EBS
Emergent BioSolutions Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 25 ▲ Emergent BioSolutions announced a $54 million contract extension wit…
- Apr 1 ▼ 1 insider sell $33.8K at $8.44
- Apr 16 ▼ Emergent BioSolutions announced a $150 million term loan refinancing…
- Apr 30 to May 1 ▼ 2 days of insider sells: $518.2K by 4 insiders, avg $8.37
- Apr 30 Emergent BioSolutions reported Q1 2026 adjusted net income per dilut…
- Jun 4 Contract: Emergent BioSolutions Supports Victoria’s Voice Foundation…
- Jun 29 Contract: Emergent BioSolutions Secures Contract Modification Valued…
- Jul 1 ▼ 1 insider sell $25.2K at $8.40
- Aug 31 Contract: Emergent BioSolutions Awarded Government of Canada Standin…
- Aug 31 FDA: Emergent BioSolutions Reinforces Commitment to Opioid Over…
- Oct 1 to Oct 7 ▼ 2 days of insider sells: $145.8K by 2 insiders, avg $7.01
- Nov 2 ▼ Emergent BioSolutions reported Q3 2026 total revenue of $110.0M, dow…
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $723.0K.
- InstitutionsMIXED
Q3 2026: 21 added (0 new), 15 trimmed or exited.
- AnalystsBULLISH
5 of 7 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate $0.280 → −$0.164 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +4.1% to 10.08M shares. 10.1 days to cover, ≈19.6% of shares.
- TrendDOWNTREND
11% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | DOUBLED | $4.8M |
| FEDERATED HERMES, INC. | TRIM | $3.1M |
| Russell Investments Group, Ltd. | TRIM | $3.1M |
| PANAGORA ASSET MANAGEMENT INC | ADD | $3.0M |
| Squarepoint Ops LLC | DOUBLED | $2.1M |
| TRUIST FINANCIAL CORP | DOUBLED | $1.5M |
| Quantinno Capital Management LP | DOUBLED | $728.1K |
| Creative Planning | ADD | $719.6K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
7 analystsPrice is below the lowest target. Median implies +72%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 9, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 10, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
DeGolyer Donald W Director Oct 7, 2026 | SELL | $126.2K |
Williams Paul Anthony SVP, Products Business Oct 1, 2026 | SELL | $19.6K |
Williams Paul Anthony SVP, Products Business Jul 1, 2026 | SELL | $25.2K |
Hartzel William SVP, Bioservices Jun 8, 2026 | TAX W/H | $13.9K |
Glessner Coleen EVP, Quality & Ethics, and CPL Jun 8, 2026 | TAX W/H | $16.1K |
LINDAHL RICHARD S EVP, Chief Financial Officer Jun 8, 2026 | TAX W/H | $31.7K |
Williams Paul Anthony SVP, Products Business Jun 8, 2026 | TAX W/H | $5.6K |
Zoon Kathryn C Director May 1, 2026 | SELL | $9.5K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.16 | -$0.22–-$0.11 | -107.2% | $137.7M |
| Next Q | -$0.53 | -$0.53–-$0.53 | -1225.0% | $175.0M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026| Nov 3, 2026 | Volatility Pause | Resumed |
SecBot reports
18 filings · 5 press releases · 1 bullish · 2 bearish · 1 mixed · 14 neutral- NEUTRAL INST-CLUSTERNov 16, 2026
Institutional activity in EBS during Q2 2026 was mixed: 22 buyers added $12.3M in net new positions while 13 sellers reduced holdings by $11.6M, resulting in a near-balanced aggregate. The cluster is dominated by passive and asset manager funds, with no insider buying corroboration, and the data…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Oak Hill Advisors LP filed an amended Schedule 13G disclosing a 7.5% passive stake in Emergent BioSolutions as of September 30, 2026, up from a prior position. The stake includes 4,014,015 shares of common stock and 2,500,000 shares issuable upon exercise of warrants.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
American Century Investment Management filed an amended Schedule 13G disclosing a 6.5% passive stake in Emergent BioSolutions as of September 30, 2026, up from a prior position. The filing follows a Q3 earnings report showing a 52% revenue decline and lowered guidance, and the increase is a…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 4, 2026
Emergent BioSolutions announced a $22.3 million delivery order modification from the U.S…
Monitor future DoD and BARDA contract modifications for BioThrax and CYFENDUS, as these government orders represent a recurring revenue stream. The company's reliance on government contracts for its…
All EBS filing & press-release reports (23)
- INST-CLUSTER reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 4, 2026
- 8-K reportNov 2, 2026
- INST-CLUSTER reportOct 30, 2026
- 8-K reportOct 16, 2026
- 144 reportOct 7, 2026
- 8-K reportJun 29, 2026
- PRESS-RELEASE reportJun 4, 2026
- CLUSTER reportApr 30, 2026
- PRESS-RELEASE reportApr 30, 2026
- PRESS-RELEASE reportApr 29, 2026
- PRESS-RELEASE reportApr 29, 2026
- DEFA14A reportApr 28, 2026
- PRESS-RELEASE reportApr 28, 2026
- DEFA14A reportApr 27, 2026
- PRESS-RELEASE reportApr 16, 2026
- PRESS-RELEASE reportApr 16, 2026
- DEFA14A reportApr 16, 2026
- DEFA14A reportApr 16, 2026
- PRESS-RELEASE reportMar 25, 2026
- DEFA14A reportMar 20, 2026